ScholarLens Back to search
2018•NeurologyRequires access

Reduced Healthcare Costs Among Clobazam-Treated Patients With Lennox–Gastaut Syndrome (P6.287)

John M. Stern, Augustina Ogbonnaya, Edward Tuttle, Wendy Y. Cheng, Georgia Montouris, J. Eric Piña-Garza, Steven Kymes, Tasneem Lokhandwala, Francis Vekeman, C. François

Open publisher page 0 citations

Abstract

To compare healthcare costs in patients with probable Lennox–Gastaut syndrome (LGS) before and after clobazam (CLB) initiation and to evaluate the impact of CLB availability on healthcare costs regardless of CLB use.

About this research paper

What this paper is about

To compare healthcare costs in patients with probable Lennox–Gastaut syndrome (LGS) before and after clobazam (CLB) initiation and to evaluate the impact of CLB availability on healthcare costs regardless of CLB use.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To compare healthcare costs in patients with probable Lennox–Gastaut syndrome (LGS) before and after clobazam (CLB) initiation and to evaluate the impact of CLB availability on healthcare costs regardless of CLB use.

Key concepts: Clobazam, Lennox–Gastaut syndrome, Medicine, Health care, Pediatrics, Epilepsy, Psychiatry, Economics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Reduced Healthcare Costs Among Clobazam-Treated Patients With Lennox–Gastaut Syndrome (P6.287) — Research Paper | ScholarLens